Coya Therapeutics’ (COYA) Buy Rating Reaffirmed at Chardan Capital

Coya Therapeutics (NASDAQ:COYA)‘s stock had its “buy” rating reaffirmed by equities research analysts at Chardan Capital in a note issued to investors on Wednesday, Benzinga reports. They currently have a $14.00 price target on the stock. Chardan Capital’s target price would indicate a potential upside of 89.96% from the stock’s previous close.

Separately, HC Wainwright assumed coverage on shares of Coya Therapeutics in a research note on Monday, September 16th. They set a “buy” rating and a $18.00 price objective on the stock.

Coya Therapeutics Price Performance

NASDAQ COYA opened at $7.37 on Wednesday. The company has a fifty day moving average of $6.86 and a 200 day moving average of $7.10. The company has a market capitalization of $107.73 million, a PE ratio of -8.67 and a beta of 0.58. Coya Therapeutics has a 1 year low of $4.40 and a 1 year high of $10.69.

Coya Therapeutics (NASDAQ:COYA) last issued its quarterly earnings data on Monday, August 12th. The company reported ($0.19) earnings per share (EPS) for the quarter. The firm had revenue of $3.43 million during the quarter. Research analysts expect that Coya Therapeutics will post -1.27 earnings per share for the current year.

Institutional Investors Weigh In On Coya Therapeutics

Several hedge funds have recently modified their holdings of COYA. Vanguard Group Inc. raised its holdings in Coya Therapeutics by 772.3% in the 1st quarter. Vanguard Group Inc. now owns 847,490 shares of the company’s stock worth $8,407,000 after purchasing an additional 750,338 shares during the period. GHP Investment Advisors Inc. acquired a new position in shares of Coya Therapeutics during the 3rd quarter worth approximately $169,000. Renaissance Technologies LLC purchased a new position in shares of Coya Therapeutics during the 2nd quarter valued at approximately $101,000. Finally, Gilbert & Cook Inc. acquired a new stake in Coya Therapeutics in the 2nd quarter valued at $61,000. 39.75% of the stock is owned by hedge funds and other institutional investors.

About Coya Therapeutics

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.